Chiesi
| Chiesi
|
|
|---|---|
 |
|
| legal form | GmbH |
| founding | 2002 as Asche Chiesi GmbH, since 2009 Chiesi GmbH |
| Seat |
Hamburg , Germany
|
| management | Thomas Gauch |
| Number of employees | 350 (as of May 2019) |
| sales | € 216 million (2018) |
| Branch | Pharmacy, human medicine |
| Website | www.chiesi.de |
The Chiesi GmbH is a German pharmaceutical company based in Hamburg . It is a subsidiary of the Italian Chiesi Farmaceutici SpA, based in Parma, Italy . Three medicines sold by Chiesi are on the WHO Essential Medicines List.
Corporate structure
Chiesi employs around 5,600 people at its headquarters in Italy and in the 28 subsidiaries around the world and generated around € 1.786 billion in sales in the 2018 financial year. The company also received B Corporation certification in June 2019 . This award is aimed at companies that meet the highest standards in terms of demonstrable social and environmental performance, public transparency and legal responsibility in order to reconcile profit and social added value.
Chiesi GmbH in Germany is one of the largest sales companies in the group. The employees in the office and in the field primarily deal with the marketing of drugs from the four therapeutic areas of respiratory tract, neonatology, rare diseases and transplant medicine. In 2019, Chiesi GmbH was named a top employer by the TOP Employers Institute for the eighth time in a row.
The research locations are in Parma (Italy), Paris (France), Cary (USA), Lidingo (Sweden), Oxford & Chippenham (GB). A total of 788 employees work in this area, with an innovation volume of around € 382 million.
history
The Italian Chiesi Farmaceutici SpA was founded in Parma in 1935, initially as a small laboratory operation, followed by the first factory in 1955. At the end of the 1970s, the Group's first foreign branch opened in Brazil. In 1979, Chiesi launched the first asthma drug on the market. After further expansion, the company has had its own subsidiaries since 1987. a. in the following countries: China, Germany, Austria, Greece, Great Britain, Italy, Pakistan, USA.
Products
Chiesi products are e.g. Sometimes used in diseases of the respiratory tract , in neonatology , in rare diseases and in transplant medicine .
For the treatment of the rare disease α-mannosidosis , the enzyme replacement therapy Lamzede with the active ingredient velmanase alfa has been available since July 2018 .
Procysbi, with the active substance cysteamine , is used to treat the rare disease nephropathic cystinosis in children and adults.
With Holoclar , the first stem cell therapy in Europe was approved in 2015. This is used in the rare disease limbal stem cell insufficiency.
For the first gene therapeutic agent Glybera with the active ingredient alipogentiparvovec, Chiesi received the special innovation award from the Pharmazeutische Zeitung. However, there are controversial discussions about this type of therapy.
Other important products are (active ingredient and area of application in brackets):
- Beclorhinol ( beclometasone dipropionate , respiratory tract )
- Bramitob ( tobramycin , rare diseases )
- Bronchitol ( mannitol , rare diseases )
- Budiair ( budesonide , respiratory tract )
- Curosurf (phospholipid fraction, neonatology )
- Envarsus ( tacrolimus , transplant medicine )
- Forair (formoterol fumarate dihydrate, respiratory tract )
- Foster (formoterol fumarate dihydrate and beclometasone dipropionate, respiratory tract )
- Sanasthmax ( beclometasone , respiratory tract )
- Trimbow ( beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium bromide , respiratory tract )
- Peyona ( caffeine citrate , neonatology )
- Quinsair ( levofloxacin , respiratory tract )
Chiesi Foundation
The Chiesi Foundation Onlus is a non-profit organization that promotes research projects and the exchange of science among experts and supports young scientists in the medical field. In addition, humanitarian aid projects in developing countries receive grants.
Web links
Individual evidence
- ↑ [1] Retrieved July 8, 2019.
- ↑ [2] Retrieved July 8, 2019.
- ↑ [ https://www.chiesi.de/img/news/allegati/634_presseinformation-chiesi-erhalt-b-corp-zertifikation.pdf ] Retrieved on July 10, 2019.
- ↑ [ https://bcorporation.net/about-b-corps ] Retrieved July 10, 2019.
- ↑ Chiesi GmbH - Therapy Areas Retrieved on July 8, 2019.
- ↑ [3] Retrieved May 20, 2019.
- ↑ https://www.chiesi.de/jahreszahlen-2018-chiesi-züge-positive-bilanz- [Chiesi website, section "Press Release"] Accessed on May 20, 2019.
- ↑ https://www.chiesi.de/jahreszahlen-2018-chiesi-züge-positive-bilanz- [Chiesi website, section "Press Release"] Accessed on May 20, 2019.
- ↑ Chiesi website, "Products" section. Accessed July 8, 2019.
- ↑ Apotheke Adhoc online: Lamzede for alpha-mannosidosis.Retrieved on July 24, 2018.
- ↑ Apotheke Adhoc online: First stem cell therapy approved. Accessed April 26, 2016.
- ↑ Ärzteblatt online: EMA: More drugs for rare diseases. Accessed April 26, 2016.
- ^ Pharmaceutical newspaper online: PZ Innovation Award 2015. Accessed on April 26, 2016.
- ↑ WirtschaftsWoche online: Gene therapy conquers Germany. The € 1 million syringe. Accessed April 26, 2016.
- ^ Chiesi Foundation.Retrieved April 26, 2016.